article_metadata: Shumin Yuan Xiufeng Hu Yanqiu Zhao Zibing Wang
article_metadata: 10.3389/fimmu.2020.563622
article_metadata: Front Immunol
article_metadata: 2020 Nov 6;11:563622.
article_metadata: b cells pd-1 immune checkpoint inhibitor immunotherapy non-small cell lung cancer
article_metadata: CC BY
article_metadata: https://pubmed.ncbi.nlm.nih.gov/33240259/
article_metadata: Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage B-Lymphocytes / metabolism Carcinoma, Non-Small-Cell Lung / drug therapy Immune Checkpoint Inhibitors / administration & dosage Lung Neoplasms / drug therapy Lymphoma, B-Cell, Marginal Zone / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors
article_metadata: Adenocarcinoma of Lung / drug therapy Antibodies, Monoclonal, Humanized / administration & dosage B-Lymphocytes / metabolism Carcinoma, Non-Small-Cell Lung / drug therapy Immune Checkpoint Inhibitors / administration & dosage Lung Neoplasms / drug therapy Lymphoma, B-Cell, Marginal Zone / drug therapy Programmed Cell Death 1 Receptor / antagonists & inhibitors Case Reports Research Support, Non-U.S. Gov't Aged Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Agents, Phytogenic / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Bevacizumab / therapeutic use Carboplatin / therapeutic use Humans Immunologic Factors / therapeutic use Lenalidomide / therapeutic use Male Paclitaxel / therapeutic use Progression-Free Survival Rituximab / therapeutic use Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological Antineoplastic Agents, Phytogenic Immune Checkpoint Inhibitors Immunologic Factors PDCD1 protein, human Programmed Cell Death 1 Receptor Bevacizumab Rituximab sintilimab Carboplatin Lenalidomide Paclitaxel
article_metadata: PMC7681247
article_metadata: 33240259
article_metadata: Case Report: PD-1 Inhibitor Is Active in Lung Adenocarcinoma With B Cell Deficiency
article_metadata: 2020